Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study
Study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression.
Read more
Month: March 2021
Psilocybin Produces Substantial & Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer
Study finds that high-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Read more
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA.
Read more
Canada’s Largest Psychedelic Industry Conference To Coincide With Mental Health Awareness Week in May 2021
CATALYST Presents Foundation (“CATALYST”), an Alberta-based not-for-profit event company focused on advancing the psychedelic medicine movement in Canada, announced the second annual CATALYST Summit 2021, Canada’s largest conference in the psychedelic medicine arena.
Read more
